Type of Article
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Maturation and Development. Biological and Psychological Perspectives
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.46.4.375-b on 1 April 1983. Downloaded from Journal of Neurology, Neurosurgery, and Psychiatry 1983;46:375-376 definition by trained transcribers with an tumours in childhood. Book reviews interexaminer reliability of F = 0-81 fol- These volumes are much recommended Gilies de la Tourette Syndrome Volume 35 lowed by 2-way Anovas with blocking for to all neurosurgeons who wish to be of Advances in Neurology. Edited by subject pairs to compute F ratios for com- acquainted with the "state of play" in Arnold J Friedhoff and Thomas N Chase. paring the mean Z scores on each language paediatric neurosurgery. The editors are, (Pp 478; $58.90.) New York, Raven Press. function. This is incomprehensible as well however, very naive if they believe, as they 1982. as meaningless. It is impossible to find out suggest in their preface to volume 2, that it whether clonidine is really useful or not or may be "possible for paediatric This volume contains the proceedings of whether haloperidol does possess definite neurosurgeons throughout the entire world the 1981 New York symposium on advantages over other neuroleptics. to provide their knowledge and care to the Tourette syndrome. The 67 papers are This is the second major work on Gilles benefit of all children". At least 1000 mil- organised into 10 main sections, clinical de la Tourette's syndrome to appear in 4 lion of the world's population are provided and historical over-view, neuro-anatomy years, the first edited by the Shapiros, with very few neurosurgeons (for the and neuropathology, neurophysiology, Bruun, and Sweet. -
Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication
King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. -
)&F1y3x PHARMACEUTICAL APPENDIX to THE
)&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE -
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. -
Influence of CYP2D6 and CYP2C19 Gene Variants on Antidepressant
The Pharmacogenomics Journal (2014) 14, 176–181 & 2014 Macmillan Publishers Limited All rights reserved 1470-269X/14 www.nature.com/tpj ORIGINAL ARTICLE Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder EJ Brandl1,2, AK Tiwari1,2, X Zhou2,3, J Deluce2,3, JL Kennedy1,2,DJMu¨ ller1,2,4 and MA Richter1,2,3,4 Numerous studies have reported on pharmacogenetics of antidepressant response in depression. In contrast, little is known of response predictors in obsessive-compulsive disorder (OCD), a disorder with among the lowest proportion of responders to medication (40–60%). Our study is the largest investigation to date (N ¼ 184) of treatment response and side effects to antidepressants in OCD based on metabolizer status for CYP2D6 and CYP2C19. We observed significantly more failed medication trials in CYP2D6 non-extensive compared with extensive metabolizers (P ¼ 0.007). CYP2D6 metabolizer status was associated with side effects to venlafaxine (P ¼ 0.022). There were nonsignificant trends for association of CYP2D6 metabolizer status with response to fluoxetine (P ¼ 0.056) and of CYP2C19 metabolizer status with response to sertraline (P ¼ 0.064). Our study is the first to indicate that CYP genes may have a role in antidepressant response in OCD. More research is required for a future clinical application of genetic testing, which could lead to improved treatment outcomes. The Pharmacogenomics Journal (2014) 14, 176–181; doi:10.1038/tpj.2013.12; published online 2 April 2013 Keywords: obsessive-compulsive disorder (OCD); pharmacogenetics; CYP2D6; CYP2C19; treatment response INTRODUCTION OCD is widely accepted as having strong genetic influence, with Obsessive-compulsive disorder (OCD) occurs in approximately two replicated findings reported for the glutamate transporter gene percent of the population1 and is characterized by a broad variety SLC1A1 and several serotonergic, dopaminergic and other 11 of obsessions and/or compulsions causing significant distress for candidate genes. -
Pharmaceutical Appendix to the Tariff Schedule 2
Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9 -
Insomnia and Menopause: a Narrative Review on Mechanisms and Treatments
Climacteric ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/icmt20 Insomnia and menopause: a narrative review on mechanisms and treatments P. Proserpio , S. Marra , C. Campana , E. C. Agostoni , L. Palagini , L. Nobili & R. E. Nappi To cite this article: P. Proserpio , S. Marra , C. Campana , E. C. Agostoni , L. Palagini , L. Nobili & R. E. Nappi (2020): Insomnia and menopause: a narrative review on mechanisms and treatments, Climacteric, DOI: 10.1080/13697137.2020.1799973 To link to this article: https://doi.org/10.1080/13697137.2020.1799973 Published online: 03 Sep 2020. Submit your article to this journal View related articles View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=icmt20 CLIMACTERIC https://doi.org/10.1080/13697137.2020.1799973 REVIEW Insomnia and menopause: a narrative review on mechanisms and treatments P. Proserpioa, S. Marrab, C. Campanaa, E. C. Agostonia, L. Palaginic , L. Nobilib,d and R. E. Nappie aCenter of Sleep Medicine, Department of Neuroscience, Niguarda Hospital, Milan, Italy; bDINOGMI, University of Genoa, Genoa, Italy; cDepartment of Clinical Experimental Medicine, Psychiatric Unit, School of Medicine, University of Pisa, Pisa, Italy; dIRCCS G. Gaslini Institute, University of Genoa, Genoa, Italy; eResearch Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, Obstetrics and Gynecology Unit, IRCCS S. Matteo Foundation, Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Pavia, Italy ABSTRACT ARTICLE HISTORY The menopausal transition is associated with an increased frequency of sleep disturbances. Insomnia Received 12 February 2020 represents one of the most reported symptoms by menopausal women. -
European Journal of Pharmacology 753 (2015) 2–18
European Journal of Pharmacology 753 (2015) 2–18 Contents lists available at ScienceDirect European Journal of Pharmacology journal homepage: www.elsevier.com/locate/ejphar Review Serotonin: A never-ending story Berend Olivier a,b,n a Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences & Brain Center Rudolf Magnus, Utrecht University, Universiteitsweg 99, 3584CG Utrecht, The Netherlands b Department of Psychiatry, Yale University School of Medicine, New Haven, USA article info abstract Article history: The neurotransmitter serotonin is an evolutionary ancient molecule that has remarkable modulatory Accepted 16 October 2014 effects in almost all central nervous system integrative functions, such as mood, anxiety, stress, aggression, Available online 7 November 2014 feeding, cognition and sexual behavior. After giving a short outline of the serotonergic system (anatomy, Keywords: receptors, transporter) the author's contributions over the last 40 years in the role of serotonin in Serotonin depression, aggression, anxiety, stress and sexual behavior is outlined. Each area delineates the work Depression performed on animal model development, drug discovery and development. Most of the research work Anxiety described has started from an industrial perspective, aimed at developing animals models for psychiatric Aggression diseases and leading to putative new innovative psychotropic drugs, like in the cases of the SSRI SSRI fluvoxamine, the serenic eltoprazine and the anxiolytic flesinoxan. Later this research work mainly focused Fluvoxamine on developing translational animal models for psychiatric diseases and implicating them in the search for mechanisms involved in normal and diseased brains and finding new concepts for appropriate drugs. & 2014 Elsevier B.V. All rights reserved. Contents 1. Serotonin, history, drugs . -
Safety and Effectiveness of Pharmacotherapy for Depression in Adults Who Have Sustained a Traumatic Brain Injury: a Systematic Review Protocol
SYSTEMATIC REVIEW PROTOCOL Safety and effectiveness of pharmacotherapy for depression in adults who have sustained a traumatic brain injury: a systematic review protocol 1,2 1 3 1 2 4 Fiona J. Clay Luke A. Perry Amelia J. Hicks Rachel Batty Catalin Tufanaru Mahesh Jayaram 3,5 6 Jennie Ponsford Malcolm Hopwood 1Department of Psychiatry, Melbourne Neuropsychiatric Centre, The University of Melbourne, Melbourne, Australia, 2The Joanna Briggs Institute, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia, 3Monash-Epworth Rehabilitation Research Centre, Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Melbourne, Australia, 4Department of Psychiatry, University of Melbourne, Royal Melbourne Hospital, Melbourne, Australia, 5School of Psychological Sciences, Monash University, Melbourne, Australia, and 6Professorial Psychiatry Unit, Department of Psychiatry, University of Melbourne, Melbourne, Australia Review objective/question: The objective of this systematic review is to synthesize the current evidence on the effectiveness and harms of pharmacotherapy in the management of depression in adults who have sustained a traumatic brain injury. Keywords Depression; depressive symptomatology; pharmacotherapy; traumatic brain injury JBI Database System Rev Implement Rep 2017; 15(9):2270–2286. Background of TBI survivors report ongoing neurobehavioral and emotional difficulties which may include depres- raumatic brain injury (TBI) comprises a clini- 6 cally heterogeneous group of disorders caused sive symptomatology. Studies indicate that neuro- T behavioral and emotional disturbances impair by trauma inflicted on the brain by a mechanical 7,8 force of external origin. Traumatic brain injury is quality of life the most for TBI survivors. one of the most common causes of death and dis- Depression is one of the most common and dis- abling psychiatric diagnoses for individuals with ability worldwide. -
Tcas Versus Placebo - New Studies in the Guideline Update
TCAs versus placebo - new studies in the guideline update Comparisons Included in this Clinical Question Amitriptyline vs placebo Clomipramine vs placebo Dosulepin (dothiepin) vs placebo AMSTERDAM2003A LARSEN1989 FERGUSON1994B BAKISH1992B PECKNOLD1976B ITIL1993 BAKISH1992C RAMPELLO1991 MINDHAM1991 BREMNER1995 THOMPSON2001B CLAGHORN1983 CLAGHORN1983B FEIGHNER1979 GELENBERG1990 GEORGOTAS1982A GOLDBERG1980 HICKS1988 HOLLYMAN1988 HORMAZABAL1985 HOSCHL1989 KLIESER1988 LAAKMAN1995 LAPIERRE1991 LYDIARD1997 MYNORSWALLIS1995 MYNORSWALLIS1997 REIMHERR1990 RICKELS1982D RICKELS1985 RICKELS1991 ROFFMAN1982 ROWAN1982 SMITH1990 SPRING1992 STASSEN1993 WILCOX1994 16 Imipramine vs placebo BARGESCHAAPVELD2002 BEASLEY1991B BOYER1996A BYERLEY1988 CASSANO1986 CASSANO1996 CLAGHORN1996A COHN1984 COHN1985 COHN1990A COHN1992 COHN1996 DOMINGUEZ1981 DOMINGUEZ1985 DUNBAR1991 ELKIN1989 ENTSUAH1994 ESCOBAR1980 FABRE1980 FABRE1992 FABRE1996 FEIGER1996A FEIGHNER1980 FEIGHNER1982 FEIGHNER1983A FEIGHNER1983B FEIGHNER1989 FEIGHNER1989A FEIGHNER1989B FEIGHNER1989C FEIGHNER1992B FEIGHNER1993 FONTAINE1994 GELENBERG2002 GERNER1980B HAYES1983 ITIL1983A KASPER1995B KELLAMS1979 LAIRD1993 LAPIERRE1987 LECRUBIER1997B LIPMAN1986 LYDIARD1989 MARCH1990 17 MARKOWITZ1985 MENDELS1986 MERIDETH1983 Nortriptyline vs placebo NANDI1976 GEORGOTAS1986A NORTON1984 KATZ1990 PEDERSEN2002 NAIR1995 PESELOW1989 WHITE1984A PESELOW1989B PHILIPP1999 QUITKIN1989 RICKELS1981 RICKELS1982A RICKELS1987 SCHWEIZER1994 SCHWEIZER1998 SHRIVASTAVA1992 SILVERSTONE1994 SMALL1981 UCHA1990 VERSIANI1989 VERSIANI1990 -
Serotonin and Brain Function: a Tale of Two Receptors
JOP0010.1177/0269881117725915Journal of PsychopharmacologyCarhart-Harris and Nutt 725915review-article2017 Review Serotonin and brain function: a tale of two receptors Journal of Psychopharmacology 1 –30 © The Author(s) 2017 RL Carhart-Harris and DJ Nutt Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI:https://doi.org/10.1177/0269881117725915 10.1177/0269881117725915 journals.sagepub.com/home/jop Abstract Previous attempts to identify a unified theory of brain serotonin function have largely failed to achieve consensus. In this present synthesis, we integrate previous perspectives with new and older data to create a novel bipartite model centred on the view that serotonin neurotransmission enhances two distinct adaptive responses to adversity, mediated in large part by its two most prevalent and researched brain receptors: the 5-HT1A and 5-HT2A receptors. We propose that passive coping (i.e. tolerating a source of stress) is mediated by postsynaptic 5-HT1AR signalling and characterised by stress moderation. Conversely, we argue that active coping (i.e. actively addressing a source of stress) is mediated by 5-HT2AR signalling and characterised by enhanced plasticity (defined as capacity for change). We propose that 5-HT1AR-mediated stress moderation may be the brain’s default response to adversity but that an improved ability to change one’s situation and/or relationship to it via 5-HT2AR-mediated plasticity may also be important – and increasingly so as the level of adversity reaches a critical point. We propose that the 5HT1AR pathway is enhanced by conventional 5-HT reuptake blocking antidepressants such as the selective serotonin reuptake inhibitors (SSRIs), whereas the 5-HT2AR pathway is enhanced by 5-HT2AR-agonist psychedelics. -
PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE